CERE News and Press, Ceres Inc. From 05/03/23

2023-05-03 06:34:18 ET Cerevel Therapeutics press release ( NASDAQ: CERE ): Q1 GAAP EPS of -$0.67 in-line. Cash, cash equivalents, and marketable securities of $863.0 million as of March 31, 2023, expected to support seven data readouts in 2024 and fund operations into 2...

Ron Renaud to succeed Tony Coles, M.D. as CEO, effective June 12, 2023; Dr. Coles will continue as chairperson of the board Mr. Renaud brings more than 25 years of biotechnology leadership to Cerevel, including two prior CEO roles and strong financial and operational experience Em...

CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and chief executive officer Tony Coles, M.D., will present at the upcoming 20...

2023-04-25 14:10:17 ET Cerevel Therapeutics ( NASDAQ: CERE ) fell 5% after investor Perceptive Advisors said "it is not currently aware of or participating in any such discussions" about a potential strategic transaction with Cerevel, according to a 13D/A filing. Percept...

CAMBRIDGE, Mass., April 11, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced it will report first quarter 2023 financial results and business updates on Wed...

CAMBRIDGE, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics , (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and chief executive officer Tony Coles, M.D., will participate in a firesid...

2023-03-10 17:11:22 ET Summary Cerevel promised multiple data readouts in 2022 and 2023 but the major ones are now delayed until 2024. The company was spun out of Pfizer's CNS division and wants to become a major player in CNS. Its major targets are epilepsy, Parkinson's, and ...

2023-03-10 08:32:19 ET The following slide deck was published by Cerevel Therapeutics Holdings, Inc. in conjunction with this event. For further details see: Cerevel Therapeutics (CERE) Presents at the 43rd Annual Cowen Healthcare Conference - Slideshow

2023-03-08 08:46:08 ET Cantor Fitzgerald launched its coverage on Karuna Therapeutics ( NASDAQ: KRTX ) with a Neutral rating and a $214 price target, citing its lead product candidate KarXT, an oral therapy which modulates muscarinic receptors in the central nervous system and o...

CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics , (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced that chairperson and chief executive officer Tony Coles, M.D., will present at the upcoming ...